{"id":59182,"date":"2024-02-28T05:45:17","date_gmt":"2024-02-28T05:45:17","guid":{"rendered":"https:\/\/medsname.com\/xafinact\/"},"modified":"2026-05-01T10:49:15","modified_gmt":"2026-05-01T10:49:15","slug":"xafinact","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/xafinact\/","title":{"rendered":"Xafinact"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 R\u0103spuns rapid<\/h3>\n

Xafinact<\/strong> este un safinamide<\/strong> (50 mg or 100 mg) tablet \u2014 a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> utilizat pentru tratarea Boala Parkinson<\/strong>. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Safinamide adds a unique glutamate-modulating effect<\/strong> on top of MAO-B inhibition — it blocks voltage-dependent sodium channels and reduces stimulated glutamate release in the basal ganglia. Licensed only as adjunct to levodopa<\/strong>, not as monotherapy. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. Important:<\/strong> avoid combination with most antidepressants (SSRIs, SNRIs, TCAs), opioids such as pethidine and tramadol, and dextromethorphan — risk of atunci c\u00e2nd este combinat cu agen\u021bi serotoninergici (SSRI, SNRI, IMAO, tramadol, petidin\u0103, triptane, linezolidul fiind el \u00eensu\u0219i un slab inhibitor MAO). Este esen\u021bial\u0103 revizuirea strict\u0103 a medicamentelor concomitente \u00eenainte de \u00eenceperea tratamentului.<\/em>.<\/p>\n<\/div>\n

\nCe beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a>\n<\/div>\n

\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n

De ce s\u0103 comanzi de la MedsBase<\/h3>\n

Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n

What Is Xafinact?<\/h2>\n

Xafinact is an oral tablet containing safinamide 50 mg or 100 mg<\/strong>. safinamide is a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> originally introduced as Xadago<\/strong>. Xafinact is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n

Safinamide is the newest MAO-B inhibitor (approved by the EMA in 2015 and FDA in 2017). Its dual mechanism — reversible MAO-B inhibition plus<\/em> sodium-channel and glutamate modulation — was designed specifically to address levodopa-induced dyskinesia and wearing-off in fluctuating Parkinson patients. Unlike selegiline and rasagiline, it is licensed only as an adjunct to levodopa<\/strong>, never as monotherapy.<\/p>\n

How Does Xafinact (safinamide) Work?<\/h2>\n

Safinamide works through two parallel mechanisms. The dopaminergic action<\/strong> — reversible, highly selective MAO-B inhibition — raises brain dopamine levels and lengthens the effect of each levodopa dose. The non-dopaminergic action<\/strong> — voltage-dependent sodium-channel blockade and reduced stimulated glutamate release — dampens the abnormal glutamate signalling in the basal ganglia that contributes to discinezii induse de levodop\u0103<\/em>. The combination explains why safinamide reduces dyskinesia where most other dopaminergic agents would worsen it.<\/p>\n

Comparing the MAO-B Inhibitors<\/h2>\n

The three MAO-B inhibitors used in Parkinson disease — selegiline, rasagiline and safinamide — share a common mechanism but differ meaningfully in metabolites, dosing and clinical positioning:<\/p>\n\n\n\n\n\n\n\n\n\n
Caracteristic\u0103<\/th>\nSelegiline<\/th>\nRasagiline<\/th>\nSafinamide<\/th>\n<\/tr>\n<\/thead>\n
Doza tipic\u0103<\/td>\n5–10 mg\/day<\/td>\n0.5–1 mg\/day<\/td>\n50–100 mg\/day<\/td>\n<\/tr>\n
Active metabolites<\/td>\nAmphetamine + methamphetamine<\/td>\nAminoindan (non-amphetamine)<\/td>\nNo active stimulant metabolite<\/td>\n<\/tr>\n
Glutamate effect<\/td>\nNu<\/td>\nNu<\/td>\nDa<\/strong> — sodium-channel\/glutamate-release modulation<\/td>\n<\/tr>\n
Indica\u021bie<\/td>\nMonotherapy or adjunct<\/td>\nMonotherapy or adjunct<\/td>\nAdjunct only<\/strong> — for fluctuating PD on levodopa<\/td>\n<\/tr>\n
Insomnia risk<\/td>\nHigher (amphetamine metabolites)<\/td>\nSc\u0103zut<\/td>\nSc\u0103zut<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Who Is Xafinact For?<\/h2>\n

Xafinact is appropriate for adults with mid- or late-stage Parkinson disease on stable levodopa therapy who are experiencing motor fluctuations (end-of-dose wearing-off). It is prime\u0219te,<\/strong> licensed for early monotherapy — rasagiline or selegiline are the appropriate MAO-B options for that. Patients with severe hepatic impairment, retinal disease (especially albinism, retinitis pigmentosa, retinal degeneration, severe diabetic retinopathy or uveitis) should not use safinamide.<\/p>\n

Dozare \u0219i administrare<\/h2>\n

The standard regimen is 50 mg once daily for 2 weeks<\/strong> as a starting dose, then increased to 100 mg o dat\u0103 pe zi<\/strong> if tolerated. There is no benefit to higher doses; above 100 mg\/day MAO-B selectivity is lost. Take in the morning with or without food. May be combined with any standard levodopa regimen; the levodopa dose may need a small reduction (10–30%) if dyskinesia worsens.<\/p>\n\n\n\n\n\n\n\n
Faz\u0103<\/th>\nDoza<\/th>\n<\/tr>\n<\/thead>\n
Weeks 1–2<\/td>\n50 mg once daily, morning<\/td>\n<\/tr>\n
Maintenance (if 50 mg insufficient)<\/td>\n100 mg o dat\u0103 pe zi<\/td>\n<\/tr>\n
Insuficien\u021b\u0103 hepatic\u0103 sever\u0103<\/td>\nEvita\u021bi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
⚠ Tyramine and the “cheese effect”<\/strong> At standard MAO-B-selective doses, dietary tyramine restriction is generally prime\u0219te,<\/em> required. However, MAO-B selectivity is dose-dependent — selegiline above 10 mg\/day, rasagiline above 1 mg\/day, and safinamide above 100 mg\/day lose selectivity and inhibit peripheral MAO-A as well. At those doses, tyramine-rich foods (aged cheeses, cured meats, broad beans, fermented soya, draught beer) can trigger a hypertensive crisis. Stay within prescribed doses to avoid this risk.<\/div>\n

Efecte Secundare Comune<\/h2>\n

Dyskinesia (a paradoxical early effect — safinamide initially amplifies levodopa effect, so dyskinesia can increase<\/em> in the first weeks before settling), nausea, insomnia, postural hypotension, fall risk. Less common: visual hallucinations, anxiety, weight loss. Retinal toxicity<\/strong> has been a concern in animal studies but has not been seen at any meaningful frequency in humans — nonetheless, eye examination before starting and periodically is recommended for patients with pre-existing retinal disease.<\/p>\n

⚠ Serotonin syndrome — dangerous interactions<\/strong> Combining a MAO-B inhibitor with serotonergic drugs can cause atunci c\u00e2nd este combinat cu agen\u021bi serotoninergici (SSRI, SNRI, IMAO, tramadol, petidin\u0103, triptane, linezolidul fiind el \u00eensu\u0219i un slab inhibitor MAO). Este esen\u021bial\u0103 revizuirea strict\u0103 a medicamentelor concomitente \u00eenainte de \u00eenceperea tratamentului.<\/em>: agitation, sweating, tremor, hyperreflexia, fever, diarrhoea, in severe cases seizures and death. Avoid:<\/strong> SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), SNRIs (venlafaxine, duloxetine), tricyclics (amitriptyline, imipramine), pethidine (meperidine), tramadol, dextromethorphan, methadone, St John’s wort, MDMA. Wash-out periods:<\/strong> stop fluoxetine 5 weeks before starting MAO-B inhibitor; stop other SSRIs\/SNRIs at least 2 weeks before; do not start fluoxetine within 2 weeks of stopping the MAO-B inhibitor.<\/div>\n

Interac\u021biuni Medicamentoase \u0219i Alimentare<\/h2>\n